Trastuzumab deruxtecan (DS-8201a), CAS 1826843-81-5
Trastuzumab deruxtecan is an anti-HER2 antibody-drug conjugate (ADC) for targeted cancer therapy. It links a humanized anti-HER2 antibody to Dxd, a topoisomerase I inhibitor, via a cleavable peptide. This design delivers the cytotoxic agent specifically to HER2-positive cancer cells, enhancing precision and minimizing side effects.
Key Features:
- HER2 Targeting: Binds selectively to HER2 receptors found in breast, gastric, and some lung cancers.
- Mechanism of Action: Once inside HER2-positive cells, releases Dxd to inhibit topoisomerase I, causing DNA damage and cell death.
- Clinical Use: Effective for HER2-positive breast, gastric, and certain lung cancers.
Significance: Trastuzumab deruxtecan offers targeted therapy for HER2-positive cancers, including those resistant to previous treatments, with fewer off-target effects.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.